A proposed algorithm for improved recognition and treatment of the depression/anxiety spectrum in primary care

Primary Care Companion to the Journal of Clinical Psychiatry

Volumn 3, Issue 2, 2001, Pages 44-52

  Ballenger, James C ^a,e   Davidson, Jonathan R T ^b   Lecrubier, Yves ^c   Nutt, David J ^d  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

^c PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^d UNIVERSITY OF BRISTOL   (United Kingdom)

^e MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0001878048     PISSN: 15235998     EISSN: None     Source Type: Journal    
DOI: 10.4088/PCC.v03n0201     Document Type: Article

References (56)

1. Ballenger JC, Davidson JRT, Lecrubier Y, et al. Consensus Statement on panic disorder from the International Consensus Group on Depression and Anxiety. J Clin Psychiatry 1998;59(suppl 8):47-54
2. Ballenger JC, Davidson JRT, Lecrubier Y, et al. Consensus statement on social anxiety disorder from the International Consensus Group on Depression and Anxiety. J Clin Psychiatry 1998;59(suppl 17):54-60
3. Ballenger JC, Davidson JRT, Lecrubier Y et al. Consensus statement on generalized anxiety disorder from the International Consensus Group on Depression and Anxiety. J Clin Psychiatry 2001 ;62(suppl 11):53-58
4. Ballenger JC, Davidson JRT, Lecrubier Y, et al. Consensus statement on posttraumatic stress disorder from the International Consensus Group on Depression and Anxiety. J Clin Psychiatry 2000;61(suppl 5):60-66
5. Ballenger JC, Davidson JRT, Lecrubier Y, et al. Consensus statement on the primary care management of depression from the International Consensus Group on Depression and Anxiety. J Clin Psychiatry 1999;60(suppl 7):54-61
6. Ballenger JC, Davidson JRT, Lecrubier Y, et al. Consensus statement on depression, anxiety, and functional gastrointestinal disorders from the International Consensus Group on Depression and Anxiety. J Clin Psychiatry 2001;62(suppl 8):48-51
7. Ballenger JC, Davidson JRT, Lecrubier Y, et al. Consensus statement on depression, anxiety, and cardiovascular disease from the International Consensus Group on Depression and Anxiety. J Clin Psychiatry 2001;62(suppl 8):24-27
8. Ballenger JC, Davidson JRT, Lecrubier Y, et al. Consensus statement on depression, anxiety, and oncology from the International Consensus Group on Depression and Anxiety. J Clin Psychiatry 2001;62(suppl 8):64-67
9. Ballenger JC, Davidson JRT, Lecrubier Y, et al. Consensus statement on transcultural issues in depression and anxiety from the International Consensus Group on Depression and Anxiety. J Clin Psychiatry 2001;62(suppl 13):47-55
10. Ballenger JC. Treatment of panic disorder with serotonin uptake inhibitors (SSRIs) In: Montgomery SA, den Boer JA, eds. SSRIs in Depression and Anxiety. Chichester, England: John Wiley & Sons; 1998:115-134
11. Feighner JP. Overview of antidepressants currently used to treat anxiety disorders J Clin Psychiatry 1999;60(suppl 22): 18-22
12. Goodman WK, Price LH, Rasmussen SA, et al. Efficacy of fluvoxamine in obsessive-compulsive disorder: a double-blind comparison with placebo. Arch Gen Psychiatry 1989;46:36-44
13. Chouinard G. Sertraline in the treatment of obsessive compulsive disorder: two double-blind, placebo-controlled studies. Int Clin Psychopharmacol 1992;7:37-11
14. Zohar J, Judge R. Paroxetine versus clomipramine in the treatment of obsessive-compulsive disorder. Br J Psychiatry 1996;169:468-474
15. Lecrubier Y Bakker A, Dunbar G, et al, for the Collaborative Paroxetine Panic Study investigators. A comparison of paroxetine, clomipramine and placebo in the treatment of panic disorder. Acta Psychiatr Scand 1997;95:145-152
16. Lecrubier Y, Judge R, for the Collaborative Paroxetine Panic Study Investigators. Long-term evaluation of paroxetine, clomipramine and placebo in panic disorder. Acta Psychiatr Scand 1997;95:153-160
17. Ballenger JC, Wheadon DE, Steiner M, et al. Double-blind, fixed-dose, placebo-controlled study of paroxetine in the treatment of panic disorder. Am J Psychiatry 1998;155:36-42
18. Pollack MH, Otto MW, Worthington JJ, et al. Sertraline in the treatment of panic disorder: a flexible-dose multicenter trial. Arch Gen Psychiatry 1998;55:1010-1016
19. Lepola UM, Wade AG, Leinonen EV, et al. A controlled prospective, 1-year trial of citalopram in the treatment of panic disorder. J Clin Psychiatry 1998;59:528-534
20. Michelson D, Lydiard RB, Pollack MH, et al, for the Fluoxetine Panic Disorder Study Group. Outcome assessment and clinical improvement in panic disorder: evidence from a randomized controlled trial of fluoxetine and placebo. Am J Psychiatry 1998;155:1570-1577
21. Baldwin D, Bobes J, Stein DJ, et al, for the Paroxetine Study Group. Paroxetine in social phobia/social anxiety disorder: randomised, double-blind, placebo-controlled study. Br J Psychiatry 1999;175:120-126
22. Stein MB, Liebowitz MR, Lydiard RB, et al. Paroxetine treatment of generalized social phobia (social anxiety disorder): a randomized controlled trial. JAMA 1998;280:708-713
23. Stein MB, Fyer AJ, Davidson JRT, et al. Fluvoxamine treatment of social phobia (social anxiety disorder): a double-blind, placebo-controlled study. Am J Psychiatry 1999;156:756-760
24. Davidson JRT, Pharmacotherapy of social anxiety disorder. J Clin Psychiatry 1998;59(suppl 17):47-51
25. Rocca P, Fonzo V, Scotta M, et al. Paroxetine efficacy in the treatment of generalized anxiety disorder. Acta Psychiatr Scand 1997;95:444-450
26. Bellew KM, McCafferty JP, Iyengar M, et al. Paroxetine treatment of GAD: a double-blind placebo-controlled trial. In: New Research Abstracts of the 153rd Annual Meeting of the American Psychiatric Association; May 16, 2000; Chicago , Ill. Abstract NR253:124-125
27. Marshall RD, Schneier FR, Fallon BA, et al. An open trial of paroxetine in patients with noncombat-related, chronic posttraumatic stress disorder. J Clin Psychopharmacol 1998;18:10-18
28. Davidson JRT, Malik ML, Sutherland SN. Response characteristics to antidepressants and placebo in post-traumatic Stress disorder. Int Clin Psychopharmacol 1997;12:291-296
29. Connor KM, Sutherland SM, Tupler LA, et. al. Fluoxetine in post-traumatic stress disorder: randomised, double-blind study. Br J Psychiatry 1999;175:17-22
30. Meltzer-Brody S, Connor KM, Churchill EL, et al. Simptom-specific effects of fluoxetine in post-traumatic stress disorder Int Clin Psychopharmacol 2000;15:227-231
31. van der Kolk BA, Dreyfuss D, Michaels M, et al. Fluoxetine in posttraumatic stress disorder. J Clin Psychiatry 1994;55:517-522
32. Beebe KL, Pitts CD, Ruggiero L, et al. Paroxetine in the treatment of PTSD: a 12 week, placebo-controlled, multicenter study. In: Proceedings of the International Society for Traumatic Stress Studies; Nov 16-19 2000; San Antonio, Tex. Abstract F604
33. Thase ME, Simons AD, Reynolds CF III. Abnormal electroencephalographic sleep profiles in major depression: association with response to cognitive behavior therapy. Arch Gen Psychiatry 1996;53:99-108
34. Saletu-Zyhlarz G, Saletu B, Anderer P, et al. Nonorganic insomnia in generalized anxiety disorder, 1: controlled studies on sleep, awakening and daytime vigilance utilizing polysomnography and EEG mapping. Neuropsychobiology 1997;36:117-129
35. Reynolds CF III, Shaw DH, Newton TF, et al. EEG sleep in outpatients with generalized anxiety: a preliminary comparison with depressed outpatients. Psychiatry Res 1983;8:81-89
36. Kupfer DJ. Sleep research in depressive illness: clinical implications - a tasting menu. Biol Psychiatry 1995;38:391-403
37. Gunasekara NS, Noble S, Benfield P. Paroxetine: an update of its pharmacology and therapeutic use in depression and a review of its use in other anxiety disorders. Drugs 1998;55:85-120
38. Sargent PA, Kjaer KH, Bench CJ, et al. Brain serotonin 1A receptor binding measured by positron emission tomography with [11C]WAY-100635: effects of depression and antidepressant treatment. Arch Gen Psychiatry 2000;57:174-180
39. Sargent NA, Nash J, Hood S, et al. 5-HTlA receptor binding in panic disorder: comparison with depressive disorder and healthy volunteers using PET and [11C]WAY-100635. Neuroimage 2000; 11 Abstract 189
40. Delgado PL, Charney DS, Price LH, et al. Serotonin function and the mechanism of antidepressant action: reversal of antidepressant-induced remission by rapid depletion of plasma tryptophan. Arch Gen Psychiatry 1990;47:411-418
41. Smith KA, Fairburn CG, Cowen PJ. Depression relapse after rapid depletion of tryptophan. Lancet 1997;349:915-919
42. Smeraldi E, Diaferia G, Erzegovesi S, et al. Tryptophan depletion in obsessive-compulsive patients. Biol Psychiatry 1996;40:398-402
43. Barr LC, Goodman WK, McDougle CJ, et al. Tryptophan depletion in patients with obsessive-compulsive disorder who respond to serotonin reuptake inhibitors. Arch Gen Psychiatry 1994;51:309-317
44. Forshall S, Bell C, Nutt D. Relapse of panic symptoms after rapid depletion of tryptophan. Int J Neuropsychopharmacol 2000;3:S228
45. Spitzer RL, Kroenke K, Linzer M, et al. Health-related quality of life in primary care patients with mental disorders: results from the PRFMEMD 1000 Study. JAMA 1995;274:1511-1517
46. Olfson M, Leon AC, Broadhead WE, et al. The SDDS-PC: a diagnostic aid for multiple mental disorders in primary care. Psychopharmacol Bull 1995;31:415-420
47. Goldberg D, Williams P. A Users Guide to the General Healthcare Questionnaire: GHQ. 1988; Windsor, UK: NFER-NELSON; 1991
48. Zich JM, Attkisson CC, Greenfield TK. Screening for depression in primary care clinics: the CES-D and the BDI. Int J Psychiatry Med 1990;20:259-277
49. Lecrubier Y, Sheehan DV, Weiller E, et al. The Mini International Neuropsychiatric Interview (MINI): a short diagnostic structured interview: reliability and validity according to the CIDI. Eur Psychiatry 1997;12:224-231
50. Sheehan DV, Lecrubier Y, Sheehan KH, et al. The validity of the Mini International Neuropsychiatric Interview (MINI) according to SCID-P and its reliability Eur Psychiatry 1997;12:232-241
51. Sheehan DV, Lecrubier Y, Sheehan KH, et al. The Mini-International Neuropsychiatric Interview (MINI): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry 1998;59(suppl 20):22-57
52. Ustün TB, Sartorius N, eds. Mental Illness in General Health Care: An International Study. Chichester, England: John Wiley & Sons; 1995
53. World Health Organization. The Primary Health Care Version of the Composite International Diagnostic Interview: CIDI-PHC. Geneva, Switzerland. World Health Organization; 1991
54. Sheehan D. Depression and anxiety spectrum disorders. Presented at the 22nd meeting of the Collegium Internationale Neuro-Psychopharmacologicum; July 9-13, 2000; Brussels, Belgium
55. Lecrubier Y, Bobes J, Gutierez M, et al. Validation of the MINI in four European countries. Eur Psychiatry. In press
56. Ballenger JC. Current treatments of the anxiety disorders in adults. Biol Psychiatry 1999;46:1579-1594